The first Australian trials have started of a vaccine to prevent koalas from contracting and spreading the deadly sexually transmitted disease, chlamydia.

The trials—supervised by Prof Peter Timms and Prof Ken Beagley from Queensland University of Technology (QUT)’s Institute of Health and Biomedical Innovation—have been undertaken safely both in healthy koalas and koalas that already have chlamydial disease. All vaccinated koalas developed a good immune response to the anti-chlamydia vaccine, which shows great promise of making a significant impact on the disease in the near future.

Chlamydia is a major threat to the continued survival of koalas. Almost all populations in Australia are affected by the disease. It is a significant cause of infertility, urinary tract infections, and inflammation in the lining of the eye which often leads to blindness.

Koala numbers are declining across virtually its whole range. In the Koala Coast region of southeast Queensland in 2008 it was estimated that 2332 koalas had been lost in a three-year monitoring period. That represented a 51 per cent decrease.

By studying chlamydial disease in koalas, QUT researchers hope to understand the condition better in general. They believe their work may also hold the key to developing a successful vaccine for use against the human sexually transmitted disease Chlamydia trachomatis, a major cause of infertility in women.

Photo: Professor Peter Timms is trialling a Chlamydia vaccine for koalas.

Credit: QUT

Institute of Health and Biomedical Innovation, QUT, Peter Timms, Tel: +61 7 3138 6199, p.timms@qut.edu.au; www.ihbi.qut.edu.au/